Featured Research

from universities, journals, and other organizations

New treatment for an aggressive childhood cancer

Date:
September 14, 2011
Source:
IDIBELL-Bellvitge Biomedical Research Institute
Summary:
Researchers have shown that glucose metabolism inhibition with 2-deoxyglucose (2-DG) induces cell death in a type of childhood sarcoma: alveolar rhabdomyosarcoma.

A study made by IDIBELL researchers shows that glucose metabolism inhibition with 2-deoxyglucose (2-DG) induces cell death in a type of childhood sarcoma: alveolar rhabdomyosarcoma. The results have been published in the journal Cancer Research.

Related Articles


This molecule is very similar to the one used widely in positron emission tomography (PET), an imaging technique used to diagnose tumours by their glucose consumption rate. This suggests that it might be immediately repositioned as a therapy to treat an often fatal childhood cancer.

Rhabdomyosarcoma is the most common soft tissue tumour in children and adolescence, accounting for 4-5% of paediatric tumours. It occurs in two forms: embryonal rhabdomyosarcoma, the most frequent and less aggressive; and alveolar rhabdomyosarcoma, with worse prognosis.

The most widely used treatment for the latter type of sarcoma is surgery. Chemotherapy treatments are not effective and now the survival rate five years after diagnosis is 70%, which indicates that it is necessary to develop more effective treatments.

New therapeutic strategies

In this regard, in recent years it has increased interest in studying tumour metabolism as a potential therapeutic target. Several metabolic pathways have different functions in tumour cells and in healthy cells. Specifically, glycolysis (glucose oxidation for energy) is increased in some tumour cells. This makes them particularly sensitive to inhibitors of glycolysis such as 2-deoxyglucose.

The study, coordinated by the head of the group of Cell Death Regulation, Cristina Muñoz-Pinedo, and the head of the group of Sarcomas, Oscar Martinez-Tirado shows that "in vitro" this molecule inhibits the metabolism of glucose needed by tumour cells, and causing their death.

According to researcher Cristina Muñoz-Pinedo this molecule "slows the growth of tumor cells, causes their death and a percentage of them suffer a terminal differentiation, and present the appearance of healthy muscle cells."

This molecule is also very similar to that used in PET imaging techniques used to diagnose tumours with high metabolism of glucose. Because of this and the fact that there are ongoing clinical trials with other tumours, shows that, at high doses, this molecule has low toxicity and it would be relatively easy that it could be used in alveolar rhabdomyosarcoma treatment.

Muñoz-Pinedo added that "knowing the mechanism that causes cell death of tumor cells, will be useful, in the future, to find more personalized treatments."


Story Source:

The above story is based on materials provided by IDIBELL-Bellvitge Biomedical Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Ramirez-Peinado, F. Alcazar-Limones, L. Lagares-Tena, N. El Mjiyad, A. Caro-Maldonado, O. M. Tirado, C. Munoz-Pinedo. 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Research, 2011; DOI: 10.1158/0008-5472.CAN-11-0759

Cite This Page:

IDIBELL-Bellvitge Biomedical Research Institute. "New treatment for an aggressive childhood cancer." ScienceDaily. ScienceDaily, 14 September 2011. <www.sciencedaily.com/releases/2011/09/110914115840.htm>.
IDIBELL-Bellvitge Biomedical Research Institute. (2011, September 14). New treatment for an aggressive childhood cancer. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2011/09/110914115840.htm
IDIBELL-Bellvitge Biomedical Research Institute. "New treatment for an aggressive childhood cancer." ScienceDaily. www.sciencedaily.com/releases/2011/09/110914115840.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins